Open Your FREE Demat Account Now!

Global Health Ltd. Share Price

NSE
BSE

NSE : MEDANTA

BSE : 543654

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹1,205.10

High

₹1,272.90

Price Summary

Previous Close ₹1,258.30
Day's Range ₹1,205.10 - ₹1,272.90
Open ₹1,212.00
52 Week Range ₹956.00 - ₹1,544.00
Volume 1,10,709
Market Cap ₹0.03
Previous Close ₹1,260.50
Day's Range ₹1,208.05 - ₹1,272.90
Open ₹1,232.25
52 Week Range ₹955.20 - ₹1,542.00
Volume 32,219
Market Cap ₹0.03

Stocks Summary

Trade Value ( ₹ in Lacs) 1,393.05
Market Cap (₹ in Mn) 0.03
Dividend Yield(%) 0.04
Price/Earning (TTM) 58.41
TTM EPS (₹) 20.69
P/E Ratio 46.44
Book Value(₹) 7.90
PAT Margin (%) 12.56
Face Value (₹) 2.00
ROCE(%) 19.38
Trade Value ( ₹ in Lacs) 406.12
Market Cap (₹ in Mn) 0.03
Dividend Yield(%) 0.04
Price/Earning (TTM) 58.41
TTM EPS (₹) 20.69
P/E Ratio 46.44
Book Value(₹) 7.90
PAT Margin (%) 12.56
Face Value (₹) 2.00
ROCE(%) 19.38

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 10308.44 32041.46
Expenses N/A N/A
PBT 2081.41 6230.47
Operating profit 0.0 0.0
Net profit 1589.82 4615.28

Shareholding Pattern

Promoters (% Holding)

33.00%

Mutual funds (% Holding)

15.97%

Non-Institution (% Holding)

40.08%

FI/Banks/Insurance (% Holding)

0.81%

Government (% Holding)

0.00%

FII

9.92%

About Global Health Ltd.

Founded 2004
Managing Director Naresh Trehan
NSE Symbol MEDANTA

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,18,204.09 1,762.75 1,583.70 - 1,583.70
Divi's Laboratories Ltd. 2,40,780.00 9,476.50 5,647.50 - 5,647.50
Torrent Pharmaceuticals Ltd. 1,73,828.11 4,602.55 3,532.60 - 3,532.60
Zydus Lifesciences Ltd. 1,15,520.92 1,169.00 835.50 - 835.50
Lenskart Solutions Ltd. 1,13,228.83 668.05 0.00 - 0.00
Apollo Hospitals Enterprise Ltd. 1,12,367.71 7,939.35 6,696.50 - 6,696.50
Laurus Labs Ltd. 1,11,304.32 2,141.85 917.95 - 917.95
Cipla Ltd. 1,09,304.89 1,344.65 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,08,758.84 1,312.60 1,101.00 - 1,101.00
Mankind Pharma Ltd. 95,082.98 2,514.20 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Oct
27
2026
EQUITY Posted on Oct 27th 2026

Sai Parenterals informs about board meeting

Pursuant to Regulation 29 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Parenterals has informed that the Board Meeting of the Company will be held on Sunday, 01st November, 2026 at the registered office of the Company to consider, the following: 1. Un-audited financial results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 2. Limited Review Report (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 3. Any other business with the permission of the Chair. Further, with reference to our letter dated 30th September, 2026 regarding closure of trading window for dealing in shares of the Company, the company has informed that, pursuant to the Code of Conduct to Regulate, Monitor and Report Trading in Securities of the Company, the trading window shall continue to remain closed for all Designated Persons of the Company and their Immediate Relatives until 48 hours after the declaration of the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 

The above information is a part of company’s filings submitted to BSE.

Read More
Oct
27
2026
EQUITY Posted on Oct 27th 2026

Sai Parenterals informs about board meeting

Pursuant to Regulation 29 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Parenterals has informed that the Board Meeting of the Company will be held on Sunday, 01st November, 2026 at the registered office of the Company to consider, the following: 1. Un-audited financial results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 2. Limited Review Report (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 3. Any other business with the permission of the Chair. Further, with reference to its letter dated 30th September, 2026 regarding closure of trading window for dealing in shares of the Company, the company has informed that, pursuant to the Code of Conduct to Regulate, Monitor and Report Trading in Securities of the Company, the trading window shall continue to remain closed for all Designated Persons of the Company and their Immediate Relatives until 48 hours after the declaration of the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
27
2026
EQUITY Posted on Oct 27th 2026

OneSource Specialty Pharma informs about press release

OneSource Specialty Pharma has informed that it enclosed Press Release (along with Earnings presentation) issued by the Company titled ‘OneSource Announces Strong Q2FY27 Results Revenue up 37% YoY and EBITDA up 53% YoY’.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
27
2026
EQUITY Posted on Oct 27th 2026

Hester Biosciences informs about completion of tenure of independent director

Pursuant to provisions of Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Hester Biosciences has informed that, Ameetkumar Desai (DIN: 00007116) has informed the Company of his decision not to seek re-appointment for a second consecutive term as an Independent Director upon completion of his current first tenure on 27 October 2026. Consequently, effective closure of business hours on 27 October 2026, Ameetkumar Desai ceases to be an Independent Director of the Company. The Company placed on record its appreciation for the valuable contribution and support provided him during his association with the Company. The details as required under SEBI Listing Regulation read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, are enclosed. 

The above information is a part of company’s filings submitted to BSE.

Read More
Oct
27
2026
EQUITY Posted on Oct 27th 2026

Chandra Bhagat Pharma informs about disclosure

Chandra Bhagat Pharma has informed that it enclosed disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Chintan Vijay Makhecha.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Global Health Ltd. ?

The current share price of Global Health Ltd. is ₹1,258.30 as of 2026-10-27.

The market capitalisation of Global Health Ltd. is ₹32,485.78 as of 2026-10-26.

The 1-year return of Global Health Ltd. is -88.40% as of 2026-10-27.

The P/E ratio of Global Health Ltd. is 46.44 as of 2026-10-27.

The 52-week high and low of Global Health Ltd. are ₹1,544.00 and ₹956.00, respectively, as of 2026-10-27.

The dividend yield of Global Health Ltd. is 0.0414% as of2026-10-26.

You can buy Global Health Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Global Health Ltd. is Naresh Trehan.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore